Navigation Links
MannKind Corporation Reports Second Quarter Financial Results
Date:8/11/2008

, regulatory submissions, manufacturing facility and product demand, that involve risks and uncertainties. Words such as "believes", "anticipates", "plans", "expects", "intend", "will", "goal", "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the Company's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the progress, timing and results of clinical trials, difficulties or delays in seeking or obtaining regulatory approval, the manufacture of the Technosphere Insulin System, competition from other pharmaceutical or biotechnology companies, MannKind's ability to enter into any collaborations or strategic partnerships, intellectual property matters and other risks detailed in MannKind's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2007 and periodic reports on Form 10-Q and Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

(Tables to follow)

MannKind Corporation

Consolidated Statements of Operations

(Unaudited)

(in thousands, except per share amounts)

Three Months Ended Six Months Ended

June 30, June 30, June 30, June 30,


'/>"/>

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
2. MannKind to Present at Upcoming Conferences
3. MannKind Corporation Reports First Quarter Financial Results
4. MannKind to Present at the Morgan Stanley Healthcare Conference
5. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
6. Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
7. MannKind Corporation Response to Recent Market Events
8. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
9. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
10. MannKind to Present at the Wachovia 2008 Healthcare Conference
11. MannKind to Present at the Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014 Regulus Therapeutics ... company leading the discovery and development of innovative medicines ... results and highlights for the quarter ended June 30, ... financial markets close. Regulus will host ... 2014, at 5:00 pm Eastern Daylight Time to discuss ...
(Date:7/30/2014)... July 30, 2014 W. R. ... release of the REVELERIS® Prep purification system ... preparative chromatographers, and other researchers to perform both ... single unit. , With the REVELERIS® Prep purification ... preparative chromatography modes with a simple touch of ...
(Date:7/30/2014)... A study presented at the 2014 ... of CSL Behring,s C1 Inhibitor (C1-INH) concentrate in ... sensitized patients. C1-INH is a human protein and ... The study shows that post-transplant treatment with ... of complement components 3 and 4, suggesting that ...
(Date:7/30/2014)...  Replikins Ltd. today released new data on changes ... the current outbreaks, the mean Ebola Reston gene Replikin ... 1995 and 2002 was 1.1; the mean Replikin Count ... in 2013, thus predicting the current outbreaks in humans. ... shown to be able to predict outbreaks (1).  For ...
Breaking Biology Technology:Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Grace Launches New REVELERIS® Prep Purification System 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3
... researchers at Rensselaer Polytechnic Institute have developed a new ... highly efficient refrigerators and cooling systems requiring no refrigerants ... innovation are a dash of nanoscale sulfur and a ... these solid-state cooling systems are thermoelectric materials, which can ...
... Solutions announced a processor modification in the popular ComLink ... make it the most powerful augmentative, alternative communication (AAC) ... the new i7 processor is up to seven times ... longer battery life and more memory storage. ...
... AMEX: IBIO) announced today the pricing of an underwritten ... gross proceeds of approximately $10 million.  Each unit consists of ... to purchase one share of common stock.  The warrants will ... exercisable beginning one year and one day from the date ...
Cached Biology Technology:Nature Materials: Quick-cooking nanomaterials in microwave to make tomorrow's air conditioners 2Nature Materials: Quick-cooking nanomaterials in microwave to make tomorrow's air conditioners 3Nature Materials: Quick-cooking nanomaterials in microwave to make tomorrow's air conditioners 4Powerful AAC Device With IntelĀ® i7 Processor Enables Natural Communication for Stroke, ALS and Autism Patients 2iBio, Inc. Prices $10 Million Public Offering 2iBio, Inc. Prices $10 Million Public Offering 3iBio, Inc. Prices $10 Million Public Offering 4
(Date:7/30/2014)... from Bjorn Brembs, professor of neurogenetics at the Institute ... figure allowing readers and reviewers to run the underlying ... important leap forward for scientific publishing, by demonstrating a ... scholarly output. , Figure 3 in fact doesn,t really ... to F1000Research , and the figure is generated ...
(Date:7/30/2014)... in developing robust therapies for spinal cord injury (SCI), ... been slow. A great deal has been learned over ... and the environmental factors that regulate axon growth, but ... in clinically available therapeutics. Prof. Lemmon and his team ... bottleneck has many root causes, but a consensus is ...
(Date:7/30/2014)... journal Scientific Reports , published by Nature ... that while global temperature is indeed increasing, so too ... each year,s average hottest and coldest temperatures will likely ... a wider range of potential high and low temperate ... even as overall temperatures rise, we may still continue ...
Breaking Biology News(10 mins):F1000Research brings static research figures to life 2Big data confirms climate extremes are here to stay 2
... into the nanoworld, the Jlich researchers used a scanning tunneling ... the needle of a record player and registers the atomic ... a millimetre) with minuscule electric currents. However, even though the ... atom, it has not been able so far to take ...
... new simulation of oil and methane leaked into the Gulf ... could form near the source of the pollution. The research ... depths and incorporates an estimated rate of flow from the ... the Gulf from April to mid July of this year. ...
... couldn,t fly, but it used its unusually large, rigid skull--coupled ... boxer Muhammad Ali. The agile creature repeatedly attacked and ... according to results of a new study published this week ... is the first detailed look at the predatory style of ...
Cached Biology News:Juelich researchers take a look inside molecules 2Deep plumes of oil could cause dead zones in the Gulf 2Ancient 'terror bird' used powerful beak to jab like boxer 2Ancient 'terror bird' used powerful beak to jab like boxer 3Ancient 'terror bird' used powerful beak to jab like boxer 4
Mouse polyclonal antibody raised against a partial recombinant AGTRAP. NCBI Entrez Gene ID = 57085...
Mouse monoclonal antibody raised against a partial recombinant RAB11B. NCBI Entrez Gene ID = RAB11B...
... polyclonal antibody raised against a ... Immunogen: SF3B2 (NP_006833, ... partial recombinant protein with GST ... Number: NM_006842 ...
...
Biology Products: